journal article·2017-08Open access

Complement activation turnover on surfaces of nanoparticles

S.M. Moghimi, D. Simberg

Nano Today· Volume 15

Abstract

The complement system is an important component of the innate immune system, which contributes to non-specific host defence. Particulate matters, such as invading pathogens and nanomedicines, in the blood may activate the complement system through classical, lectin and alternative pathways. Complement activation can aid recognition and clearance of particulate matters by immune cells, but uncontrolled complement activation can inflict damage and be life threatening. Plasma proteins on adsorption to surfaces of nanoparticles also play a significant role in complement activation and particularly through the alternative pathway. This process is continuous and changeable in vivo; protein-complement complexes are formed on the nanoparticle surface and then released and the cycle repeats on further plasma protein deposition. This complement activation turnover poses a challenge for design of immune-safe nanomedicines.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Complement system in diseases · Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. Moghimi · Annu. Rev. Pharmacol. Toxicol. · 2012 · 52 · 48110.1146/annurev-pharmtox-010611-134623 ↗
2. Moghimi · J. Innate Immun. · 2012 · 4 · 50910.1159/000339153 ↗
3. Moghimi · Pharmacol. Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
4. Ricklin · Nat. Immunol. · 2010 · 11 · 78510.1038/ni.1923 ↗
5. Moghimi · Adv. Drug Deliv. Rev. · 2011 · 63 · 100010.1016/j.addr.2011.06.002 ↗
6. van Lookeren Campagne · Cell Microbiol. · 2007 · 9 · 209510.1111/j.1462-5822.2007.00981.x ↗
7. Moghimi · Nanomedicine · 2013 · 9 · 45810.1016/j.nano.2013.02.011 ↗
8. Klapper · Biomaterials · 2014 · 35 · 368810.1016/j.biomaterials.2013.12.085 ↗
9. Chen · Nat. Nanotechnol. · 2017
10. Jain · Nat. Rev. Clin. Oncol. · 2010 · 7 · 65310.1038/nrclinonc.2010.139 ↗
11. Moghimi · Nanomedicine · 2014 · 10 · 166110.1016/j.nano.2014.04.011 ↗
12. Park · ACS Nano · 2013 · 7 · 7332
13. Markiewski · Nat. Immunol. · 2008 · 9 · 122510.1038/ni.1655 ↗
14. Moghimi · J. Control. Release · 2014 · 190 · 55610.1016/j.jconrel.2014.03.051 ↗
15. Price · Biochim. Biophys. Acta · 2001 · 1512 · 19110.1016/S0005-2736(01)00330-3 ↗
16. Blunk · Eur. J. Pharm. Biopharm. · 1996 · 42 · 262
17. Thanki · J. Mol. Biol. · 1988 · 202 · 63710.1016/0022-2836(88)90292-6 ↗
18. Petukov · Protein Sci. · 1999 · 8 · 198210.1110/ps.8.10.1982 ↗
19. Harris · 1992
20. Andersen · ACS Nano · 2013 · 7 · 110810.1021/nn3055175 ↗
21. Moghimi · Biomaterials · 2006 · 27 · 13610.1016/j.biomaterials.2005.05.082 ↗
22. Gbadamosi · FEBS Lett. · 2002 · 523 · 33810.1016/S0014-5793(02)03710-9 ↗
23. Hamad · ACS Nano · 2010 · 4 · 662910.1021/nn101990a ↗
24. Yu · ACS Nano · 2014 · 8 · 768710.1021/nn504186b ↗
25. Simpson · Rep. Prog. Phys. · 2015 · 78 · 08650110.1088/0034-4885/78/8/086501 ↗
26. Schneider · Nature · 2009 · 458 · 89010.1038/nature07769 ↗
27. Wu · J. Immunol. · 2011 · 186 · 426910.4049/jimmunol.1003802 ↗
28. Wibroe · Nanomedicine · 2015 · 11 · 190910.1016/j.nano.2015.08.003 ↗